Form 4: ACADIA Legal Officer Reports RSU Vesting, Tax-Related Stock Sale

Jennifer J. Rhodes, EVP, Chief Legal Officer of ACADIA Pharmaceuticals, reported the vesting of 7,515 restricted stock units and a subsequent sale of 3,844 shares to cover tax obligations.

Summary

• Jennifer J. Rhodes, EVP, Chief Legal Officer, SEC of ACADIA PHARMACEUTICALS INC. (ACAD), reported transactions involving the company's common stock.
• On March 24, 2026, 7,515 restricted stock units (RSUs) vested, converting into common stock at a price of $0.
• Following the vesting, on March 25, 2026, 3,844 shares of common stock were sold at a price of $21.47 per share.
• This sale was mandatory and intended to cover withholding taxes and tax-related items associated with the RSU vesting.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• After these transactions, Jennifer J. Rhodes beneficially owns 11,280 shares of common stock and 22,547 restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation and tax management practices rather than a significant positive or negative indicator for the company's operational performance or future prospects.

Positives

• The vesting of restricted stock units indicates continued compensation and retention of a key executive.
• The sale was explicitly stated as mandatory to cover tax obligations, not a discretionary sale indicating a lack of confidence.

Negatives

• A reduction in direct common stock ownership by a key executive, although explained as tax-related.

Future Outlook

The remaining restricted stock units held by Jennifer J. Rhodes are scheduled to vest in four equal annual installments, commencing on March 24, 2026.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting followed by tax-related sales, are common occurrences in the biotechnology and pharmaceutical industry, reflecting standard executive compensation practices. These transactions typically do not signal a change in company fundamentals or executive sentiment, unlike discretionary open-market sales.

Comparison to Industry Standards

• This type of transaction (vesting of RSUs and subsequent sale for tax purposes) is a standard practice for executive compensation across publicly traded companies, including those in the pharmaceutical sector like Pfizer, Johnson & Johnson, and Merck.
• The structure aligns with common equity incentive plans designed to align executive interests with shareholder value over time, with tax obligations being a necessary component of such compensation.

Stakeholder Impact

• Shareholders: Minor impact as it's a routine executive compensation event, not indicative of operational changes.
• Management: Jennifer J. Rhodes' compensation structure is partially realized, aligning her interests with long-term company performance.

Next Steps

• Remaining restricted stock units will vest in four equal annual installments starting March 24, 2026.

Key Dates

Keywords

ACADIA Pharmaceuticals, ACAD, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Jennifer J. Rhodes, Stock Sale, Rule 10b5-1